An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

Recruiting now

Conditions studied: Von Willebrand Disease (vWD)

In brief

This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF). During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.

Key facts

Study ID

NCT07404644

Run by

Takeda

People needed

13

Starts

2026-02-19

Expected to finish

2031-05-30

Last updated by the study team

2026-02-23

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Under 18 years old with vWD.
• Participants who are treated with rVWF for the purpose of hemostatic treatment and management during bleeding episodes or perioperative periods.
• Participants who have prescription or administration after the approval date of rVWF for pediatric use in Japan.

You may not qualify if…

• Patients who are participating in clinical trials of rVWF.

Where it is running

• Takeda selected site — Tokyo, Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.